Statements (139)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquired |
gptkb:Aventis
gptkb:Genzyme_Corporation |
| gptkbp:acquisition |
gptkb:Amunix_Pharmaceuticals
gptkb:Bioverativ gptkb:Boehringer_Ingelheim's_animal_health_business gptkb:Chattem gptkb:Genzyme gptkb:Kymab gptkb:Medi_Gene_AG gptkb:Provention_Bio gptkb:Apexigen gptkb:Sangamo_Therapeutics gptkb:Ablynx Translate Bio Acquired Genzyme in 2011 |
| gptkbp:ceo |
gptkb:Paul_Hudson
|
| gptkbp:clinical_trial |
over 35,000
Phase 3 conducts numerous clinical trials annually conducts clinical research in various fields conducts clinical trials globally |
| gptkbp:collaboration |
with WHO
|
| gptkbp:conducts_research_on |
gptkb:John_Francis_Reed
|
| gptkbp:cultural_diversity |
promotes workplace diversity
|
| gptkbp:developed_by |
gptkb:vaccine
|
| gptkbp:employees |
Approximately 100,000
around 100,000 over 100,000 |
| gptkbp:focus |
Pharmaceuticals and Vaccines
|
| gptkbp:focus_area |
vaccines
|
| gptkbp:founded |
gptkb:2004
|
| gptkbp:global_presence |
Operates in over 100 countries
operates in over 100 countries strong global presence |
| gptkbp:headquarters |
gptkb:Paris,_France
|
| gptkbp:healthcare |
prescription drugs
over-the-counter products consumer healthcare products |
| https://www.w3.org/2000/01/rdf-schema#label |
Sanofi
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:innovation |
invests in innovative therapies
|
| gptkbp:instruction_set |
has a diverse product pipeline
|
| gptkbp:is_vulnerable_to |
gptkb:European_Medicines_Agency_(EMA)
2-8 degrees Celsius protein subunit vaccine Vidprevtyn up to 90% in trials |
| gptkbp:manufacturing_sites |
multiple locations worldwide
|
| gptkbp:market |
operates in over 100 countries
|
| gptkbp:market_cap |
approximately €100 billion (2021)
€100 billion (2021) |
| gptkbp:number_of_employees |
around 100,000
|
| gptkbp:operates_in |
gptkb:pharmaceuticals
over 100 countries |
| gptkbp:partnership |
gptkb:GSK
gptkb:Regeneron_Pharmaceuticals with academic institutions Partnership with various biotech firms with biotech companies GSK for COVID-19 vaccine U. S. government for vaccine distribution UNICEF for immunization programs WHO for vaccine distribution biotech companies for drug development government agencies for public health initiatives various academic institutions for research |
| gptkbp:philanthropy |
gptkb:Sanofi_Espoir_Foundation
|
| gptkbp:product_line |
gptkb:medical_devices
antibiotics nutritional products biologics hormonal therapies antiviral drugs pain relief medications biosimilars gene therapies cell therapies cardiovascular drugs dermatology products allergy medications vaccines for infectious diseases OTC allergy products OTC children's health products OTC cold and flu products OTC digestive health products OTC men's health products OTC oral care products OTC pain relief products OTC skin care products OTC vitamins and supplements OTC women's health products |
| gptkbp:products |
gptkb:diabetes
gptkb:Dupixent gptkb:Lantus Vaccines vaccines Oncology drugs Cardiovascular drugs diabetes medications Rare disease treatments cardiovascular medications oncology medications |
| gptkbp:research_and_development |
gptkb:John_Francis_Reed
€6 billion (2020) Invests heavily in R& D |
| gptkbp:research_areas |
gptkb:diabetes
vaccines central nervous system disorders cardiovascular diseases infectious diseases pain management |
| gptkbp:research_focus |
neurology
oncology rare diseases vaccines immunology |
| gptkbp:revenue |
€36.1 billion (2020)
€36 billion (2020) |
| gptkbp:stock_exchange |
gptkb:Euronext_Paris
|
| gptkbp:stock_symbol |
gptkb:SAN
|
| gptkbp:subsidiaries |
gptkb:Sanofi_Genzyme
gptkb:Sanofi_Aventis gptkb:Sanofi_Pasteur |
| gptkbp:subsidiary |
gptkb:Sanofi_Genzyme
gptkb:Sanofi_Pasteur |
| gptkbp:sustainability |
committed to sustainability initiatives
|
| gptkbp:sustainability_initiatives |
diversity and inclusion programs
community engagement programs commitment to access to medicines employee health and safety programs focus on environmental responsibility |
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:traded_on |
gptkb:Euronext_Paris
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
www.sanofi.com
sanofi.com |
| gptkbp:bfsParent |
gptkb:biotechnology
|
| gptkbp:bfsLayer |
3
|